A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Elarekibep (Primary) ; Elarekibep (Primary) ; Elarekibep (Primary)
 - Indications Asthma
 - Focus Adverse reactions; First in man
 - Sponsors Pieris Pharmaceuticals
 
Most Recent Events
- 01 Aug 2019 Results presented in the Pieris Pharmaceuticals media release.
 - 01 Aug 2019 According to a Pieris Pharmaceuticals media release, data from this trial were presented at the 2019 American Thoracic Society International Conference earlier this year.
 - 22 May 2019 According to a Pieris Pharmaceuticals media release, data will be presented at an upcoming medical meeting.